Digoxin-like immunoreactivity in the serum of neonates and uremic patients, as measured in the Abbott TDX.

Yatscoff, Randall W.; Desjardins, Paul; Dalton, JR

doi:10.1093/clinchem/30.4.588

Cited by 22 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interference with a digoxin-like immunoreactive substance, as described by various authors during the past (30)(31)(32)(33), is not likely to influence this correlation using the present digoxin RIA kit.…”

Section: Discussionmentioning

confidence: 56%

Estimation of Digoxin Dosage in VLBW Infants Using Serum Creatinine Concentrations

Gortner

Hellenbrecht

1986

Acta Paediatrica

View full text Add to dashboard Cite

Digoxin steady state plasma concentrations (Css) and the corresponding serum creatinine concentrations were studied in 17 VLBW infants. Birth weight was in the range of 760-1 500 g (mean 1 068 g), gestational age ranged from 26 to 32 weeks (mean 28.7 weeks). Digoxin steady state plasma concentrations were found in the range of 0.5-6.5 ng/ml (mean 1.88 ng/ml) during maintenance therapy with 1.6-8.4 micrograms/kg BW/24 h (mean 4.4 micrograms/kg BW/24 h) given in two divided doses intravenously. No digoxin-like immunoreactive substance could be detected in the plasma of 18 infants (10 patients with a birth weight less than or equal to 1 500 g, 8 patients with a birth weight of 2 100-4 730 g) that were not treated with digoxin. The calculated digoxin clearance ranged from 0.38-4.03 ml/min/kg BW. Serum creatinine concentrations were found in the range of 35-274 mumol/l (0.4-3.1 mg/100 ml). A hyperbolic correlation may be derived from the digoxin clearance and the corresponding serum creatinine concentration. A linear relationship was observed between the dose normalized digoxin concentrations (y = Css/dose in 24 h) and the respective creatinine concentrations x (y = 0.52x-0.05; n = 17; s = 0.24; r = 0.86; p less than 0.01). According to this equation we suggest a dosing schedule for digoxin in VLBW infants with impaired renal function. Digoxin maintenance dose is derived from the digoxin target and the creatinine serum concentration. This dose recommendation proved reliable on four VLBW infants (birth weight 770-1 260 g) with decreased renal function.

show abstract

Section: Discussionmentioning

confidence: 56%

Estimation of Digoxin Dosage in VLBW Infants Using Serum Creatinine Concentrations

Gortner

Hellenbrecht

1986

Acta Paediatrica

View full text Add to dashboard Cite

show abstract

“…Several studies showed that the TDX system (Abbott GmbH Diagnostika, Wiesbaden, Germany) can measure DLIF, but compared to other immunological techniques the interference was generally less than that seen in commonly used RIAs for digoxin [33,34]. This may be due to the recommended removal of serum proteins for the use of this technique [35].…”

Section: Measurement Of Digoxin-like Immunoreactive Factormentioning

confidence: 99%

Influence of digoxin‐like immunoreactive factor on late complications in patients with diabetes mellitus

Straub

Elbracht

Krämer

et al. 1994

Eur J Clin Investigation

View full text Add to dashboard Cite

Abstract. The aim of this study was to compare the intensity of typical late complications in diabetic patients (/? = 65, 28 type I, 37 type II) who were not on glycoside drugs with low vs. high serum levels of digoxin-like immunoreactive factor (DLIF: group I, n = 42, DLIF ^ the detection limit of 0*2 ng ml 1 ; and group II, // = 23, meaniSEM: H7±0-31 [0-25-4-96] ng ml" 1 ). For detection of nephropathy, urinary albumin excretion (24 h) and creatinine clearance tests were used. For coronary heart disease a questionnaire and standard ECG; for peripheral occlusive vascular disease a questionnaire; for eye disease a fundoscopy; for neuropathy a neurological score system; and for autonomic neuropathy a standardized test battery was employed. Patients with high DLIF levels showed better test results in vibratory perception (95-7±l-5 vs. 82-8±3-8%, normal finding = 100%, 2p = 0016), had better percentile localizations concerning maximal pupillary area in darkness (28-4±6-6 vs. 8-1 ±1-8%, 2p = 0-0004), contraction velocity at 1 s (21-5±5-8 vs. 8-0±2-2%, 2p = 0-012), and dilation velocity at 6 s (23-0±6-8 vs. 10-5±2-5%, 2p = 0-041), had less retinopathy (with retinopathy: 26-1% vs. 64-3%, 2p = 0-0028), and better percentile localizations in the respiratory sinus arrhythmia test (68-4±7*3 vs. 44-1 ±49%, 2p = 0-0064). There was no difference concerning nephropathy, blood pressure, coronary heart disease and peripheral vascular disease. Separate analysis according to the type of diabetes confirmed the results in each group. This would indicate that DLIF is a possible protective endogenous substance for eye disease, and peripheral (large sensory fibres) and autonomic neuropathy in diabetic subjects independent of the type of diabetes.

show abstract

A Comparative Trial of Digoxin and Digitoxin in the Treatment of Congestive Heart Failure

et al. 1988

View full text Add to dashboard Cite

A randomized, crossover, single-blind study compared the efficacy and dosing accuracy of digoxin and digitoxin in 15 ambulatory patients wth congestive heart failure. Loading doses and maintenance doses were calculated according to published equations that adjust for sex, height, and lean body weight (for digitoxin), plus estimated creatinine clearance (for digoxin). At each 2-week visit, serum drug concentrations were measured and compliance with the prescribed regimen was assessed by tablet count. At the end of each study period, a congestive heart failure (CHF) score was determined in a blinded fashion by the same physician. Patient compliance was unusually high (greater than or equal to 80%) at every visit. Therapeutic concentrations were achieved with digoxin and digitoxin in 5 and 14 patients, respectively (p less than 0.05). During digitoxin therapy, CHF scores were lower than pretreatment values (p less than 0.05). The difference between CHF scores during the digoxin and digitoxin periods did not achieve significance (0.05 less than p less than 0.06). Therapeutic serum concentrations can be achieved more easily and frequently with digitoxin than digoxin without compromising the patient's CHF status.

show abstract

Digoxin-like immunoreactivity in the serum of neonates and uremic patients, as measured in the Abbott TDX.

Cited by 22 publications

References 0 publications

Estimation of Digoxin Dosage in VLBW Infants Using Serum Creatinine Concentrations

Estimation of Digoxin Dosage in VLBW Infants Using Serum Creatinine Concentrations

Influence of digoxin‐like immunoreactive factor on late complications in patients with diabetes mellitus

A Comparative Trial of Digoxin and Digitoxin in the Treatment of Congestive Heart Failure

Contact Info

Product

Resources

About